nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Lisinopril—Nateglinide—type 2 diabetes mellitus	0.11	0.162	CrCrCtD
Lisdexamfetamine—Aspartame—Nateglinide—type 2 diabetes mellitus	0.0874	0.129	CrCrCtD
Lisdexamfetamine—Lacosamide—Nateglinide—type 2 diabetes mellitus	0.0874	0.129	CrCrCtD
Lisdexamfetamine—Lisinopril—Ramipril—type 2 diabetes mellitus	0.0669	0.0986	CrCrCtD
Lisdexamfetamine—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0623	1	CbGbCtD
Lisdexamfetamine—Phenacemide—Nateglinide—type 2 diabetes mellitus	0.0593	0.0873	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Nateglinide—type 2 diabetes mellitus	0.0575	0.0847	CrCrCtD
Lisdexamfetamine—Amphetamine—Nateglinide—type 2 diabetes mellitus	0.0575	0.0847	CrCrCtD
Lisdexamfetamine—Methamphetamine—Nateglinide—type 2 diabetes mellitus	0.0559	0.0823	CrCrCtD
Lisdexamfetamine—Aspartame—Ramipril—type 2 diabetes mellitus	0.0532	0.0783	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Nateglinide—type 2 diabetes mellitus	0.0438	0.0645	CrCrCtD
Lisdexamfetamine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00302	0.327	CbGeAlD
Lisdexamfetamine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00203	0.22	CbGeAlD
Lisdexamfetamine—SLC6A3—nerve—type 2 diabetes mellitus	0.00142	0.153	CbGeAlD
Lisdexamfetamine—Amphetamine—CARTPT—type 2 diabetes mellitus	0.00131	0.304	CrCbGaD
Lisdexamfetamine—SLC6A2—nerve—type 2 diabetes mellitus	0.00114	0.124	CbGeAlD
Lisdexamfetamine—Phenelzine—AOC3—type 2 diabetes mellitus	0.00105	0.244	CrCbGaD
Lisdexamfetamine—Labetalol—ADRB3—type 2 diabetes mellitus	0.000695	0.162	CrCbGaD
Lisdexamfetamine—ADRA1B—kidney—type 2 diabetes mellitus	0.000648	0.0701	CbGeAlD
Lisdexamfetamine—SLC18A2—adipose tissue—type 2 diabetes mellitus	0.000578	0.0626	CbGeAlD
Lisdexamfetamine—SLC18A2—liver—type 2 diabetes mellitus	0.000406	0.0439	CbGeAlD
Lisdexamfetamine—Lisinopril—ACE—type 2 diabetes mellitus	0.0004	0.093	CrCbGaD
Lisdexamfetamine—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.0002	0.00109	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.0002	0.00109	CcSEcCtD
Lisdexamfetamine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000199	0.00108	CcSEcCtD
Lisdexamfetamine—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000198	0.00108	CcSEcCtD
Lisdexamfetamine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000198	0.00108	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000198	0.00108	CcSEcCtD
Lisdexamfetamine—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000198	0.00108	CcSEcCtD
Lisdexamfetamine—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000198	0.00108	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000197	0.00107	CcSEcCtD
Lisdexamfetamine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000197	0.00107	CcSEcCtD
Lisdexamfetamine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000197	0.00107	CcSEcCtD
Lisdexamfetamine—Convulsion—Orlistat—type 2 diabetes mellitus	0.000197	0.00107	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000197	0.00107	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000196	0.00107	CcSEcCtD
Lisdexamfetamine—Tremor—Metformin—type 2 diabetes mellitus	0.000196	0.00107	CcSEcCtD
Lisdexamfetamine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000195	0.00106	CcSEcCtD
Lisdexamfetamine—Anxiety—Valsartan—type 2 diabetes mellitus	0.000195	0.00106	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000194	0.00106	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000194	0.00105	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000193	0.00105	CcSEcCtD
Lisdexamfetamine—Anxiety—Orlistat—type 2 diabetes mellitus	0.000193	0.00105	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000192	0.00105	CcSEcCtD
Lisdexamfetamine—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000192	0.00104	CcSEcCtD
Lisdexamfetamine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000191	0.00104	CcSEcCtD
Lisdexamfetamine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000189	0.00103	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000189	0.00103	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000188	0.00102	CcSEcCtD
Lisdexamfetamine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000188	0.00102	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000188	0.00102	CcSEcCtD
Lisdexamfetamine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000187	0.00102	CcSEcCtD
Lisdexamfetamine—Rash—Glipizide—type 2 diabetes mellitus	0.000186	0.00101	CcSEcCtD
Lisdexamfetamine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000186	0.00101	CcSEcCtD
Lisdexamfetamine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000186	0.00101	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000185	0.00101	CcSEcCtD
Lisdexamfetamine—Headache—Glipizide—type 2 diabetes mellitus	0.000185	0.00101	CcSEcCtD
Lisdexamfetamine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000185	0.00101	CcSEcCtD
Lisdexamfetamine—Palpitations—Metformin—type 2 diabetes mellitus	0.000185	0.00101	CcSEcCtD
Lisdexamfetamine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000185	0.00101	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000184	0.001	CcSEcCtD
Lisdexamfetamine—Hepatitis—Ramipril—type 2 diabetes mellitus	0.000183	0.000997	CcSEcCtD
Lisdexamfetamine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000182	0.000992	CcSEcCtD
Lisdexamfetamine—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000182	0.000992	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000182	0.000991	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000182	0.000989	CcSEcCtD
Lisdexamfetamine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000182	0.000989	CcSEcCtD
Lisdexamfetamine—Agitation—Irbesartan—type 2 diabetes mellitus	0.000182	0.000988	CcSEcCtD
Lisdexamfetamine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000182	0.000988	CcSEcCtD
Lisdexamfetamine—Hypertension—Metformin—type 2 diabetes mellitus	0.000181	0.000984	CcSEcCtD
Lisdexamfetamine—Urticaria—Glyburide—type 2 diabetes mellitus	0.000181	0.000983	CcSEcCtD
Lisdexamfetamine—Nervousness—Losartan—type 2 diabetes mellitus	0.000181	0.000983	CcSEcCtD
Lisdexamfetamine—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000181	0.000982	CcSEcCtD
Lisdexamfetamine—Skin disorder—Orlistat—type 2 diabetes mellitus	0.00018	0.00098	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.00018	0.000978	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000179	0.000975	CcSEcCtD
Lisdexamfetamine—Anorexia—Valsartan—type 2 diabetes mellitus	0.000179	0.000973	CcSEcCtD
Lisdexamfetamine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000179	0.000971	CcSEcCtD
Lisdexamfetamine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000177	0.000965	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000177	0.000963	CcSEcCtD
Lisdexamfetamine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000177	0.00096	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000176	0.000959	CcSEcCtD
Lisdexamfetamine—Methamphetamine—ADRA2A—type 2 diabetes mellitus	0.000176	0.041	CrCbGaD
Lisdexamfetamine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000176	0.000958	CcSEcCtD
Lisdexamfetamine—Nausea—Glipizide—type 2 diabetes mellitus	0.000176	0.000955	CcSEcCtD
Lisdexamfetamine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000175	0.000954	CcSEcCtD
Lisdexamfetamine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000175	0.000953	CcSEcCtD
Lisdexamfetamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000175	0.000951	CcSEcCtD
Lisdexamfetamine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000175	0.00095	CcSEcCtD
Lisdexamfetamine—Tremor—Losartan—type 2 diabetes mellitus	0.000174	0.000948	CcSEcCtD
Lisdexamfetamine—Rash—Glimepiride—type 2 diabetes mellitus	0.000174	0.000946	CcSEcCtD
Lisdexamfetamine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000174	0.000945	CcSEcCtD
Lisdexamfetamine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000173	0.000943	CcSEcCtD
Lisdexamfetamine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000173	0.000942	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000173	0.000942	CcSEcCtD
Lisdexamfetamine—Headache—Glimepiride—type 2 diabetes mellitus	0.000173	0.00094	CcSEcCtD
Lisdexamfetamine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000172	0.000937	CcSEcCtD
Lisdexamfetamine—Agitation—Losartan—type 2 diabetes mellitus	0.000171	0.00093	CcSEcCtD
Lisdexamfetamine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000171	0.000928	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.00017	0.000926	CcSEcCtD
Lisdexamfetamine—Angioedema—Losartan—type 2 diabetes mellitus	0.00017	0.000924	CcSEcCtD
Lisdexamfetamine—Insomnia—Valsartan—type 2 diabetes mellitus	0.00017	0.000923	CcSEcCtD
Lisdexamfetamine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000168	0.000912	CcSEcCtD
Lisdexamfetamine—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000168	0.000912	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000168	0.000912	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000168	0.000912	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000167	0.00091	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP2E1—type 2 diabetes mellitus	0.000167	0.0389	CrCbGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000167	0.000909	CcSEcCtD
Lisdexamfetamine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000167	0.000908	CcSEcCtD
Lisdexamfetamine—Skin disorder—Metformin—type 2 diabetes mellitus	0.000166	0.000903	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000165	0.0009	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000165	0.000899	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000165	0.000899	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000165	0.000898	CcSEcCtD
Lisdexamfetamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000165	0.000895	CcSEcCtD
Lisdexamfetamine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000165	0.000895	CcSEcCtD
Lisdexamfetamine—Palpitations—Losartan—type 2 diabetes mellitus	0.000164	0.000894	CcSEcCtD
Lisdexamfetamine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000164	0.000891	CcSEcCtD
Lisdexamfetamine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000163	0.000889	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000163	0.000888	CcSEcCtD
Lisdexamfetamine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000163	0.000888	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000163	0.000887	CcSEcCtD
Lisdexamfetamine—Anorexia—Metformin—type 2 diabetes mellitus	0.000163	0.000886	CcSEcCtD
Lisdexamfetamine—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000162	0.000883	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000162	0.000881	CcSEcCtD
Lisdexamfetamine—Fatigue—Valsartan—type 2 diabetes mellitus	0.000162	0.00088	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000161	0.000878	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000161	0.000877	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000161	0.000877	CcSEcCtD
Lisdexamfetamine—Mental disorder—Ramipril—type 2 diabetes mellitus	0.00016	0.000873	CcSEcCtD
Lisdexamfetamine—Constipation—Valsartan—type 2 diabetes mellitus	0.00016	0.000873	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.00016	0.000871	CcSEcCtD
Lisdexamfetamine—Fatigue—Orlistat—type 2 diabetes mellitus	0.00016	0.00087	CcSEcCtD
Lisdexamfetamine—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000159	0.000867	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP1A2—type 2 diabetes mellitus	0.000159	0.037	CrCbGaD
Lisdexamfetamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000158	0.000861	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000158	0.00086	CcSEcCtD
Lisdexamfetamine—Anxiety—Losartan—type 2 diabetes mellitus	0.000158	0.000858	CcSEcCtD
Lisdexamfetamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000157	0.000856	CcSEcCtD
Lisdexamfetamine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000157	0.000854	CcSEcCtD
Lisdexamfetamine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000157	0.000853	CcSEcCtD
Lisdexamfetamine—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000157	0.000852	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000156	0.000848	CcSEcCtD
Lisdexamfetamine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000156	0.000848	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000156	0.000847	CcSEcCtD
Lisdexamfetamine—Nervousness—Ramipril—type 2 diabetes mellitus	0.000155	0.000843	CcSEcCtD
Lisdexamfetamine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000155	0.000842	CcSEcCtD
Lisdexamfetamine—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000154	0.000836	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000152	0.000829	CcSEcCtD
Lisdexamfetamine—Somnolence—Metformin—type 2 diabetes mellitus	0.000152	0.000827	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000152	0.000826	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00015	0.000819	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Metformin—type 2 diabetes mellitus	0.00015	0.000818	CcSEcCtD
Lisdexamfetamine—Tremor—Ramipril—type 2 diabetes mellitus	0.000149	0.000813	CcSEcCtD
Lisdexamfetamine—Urticaria—Valsartan—type 2 diabetes mellitus	0.000149	0.000811	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000149	0.00081	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000149	0.000808	CcSEcCtD
Lisdexamfetamine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000148	0.000806	CcSEcCtD
Lisdexamfetamine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000148	0.000804	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000148	0.000803	CcSEcCtD
Lisdexamfetamine—Fatigue—Metformin—type 2 diabetes mellitus	0.000147	0.000802	CcSEcCtD
Lisdexamfetamine—Urticaria—Orlistat—type 2 diabetes mellitus	0.000147	0.000801	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP2E1—type 2 diabetes mellitus	0.000147	0.0343	CrCbGaD
Lisdexamfetamine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000147	0.000798	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000147	0.000797	CcSEcCtD
Lisdexamfetamine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000147	0.000797	CcSEcCtD
Lisdexamfetamine—Agitation—Ramipril—type 2 diabetes mellitus	0.000147	0.000797	CcSEcCtD
Lisdexamfetamine—Constipation—Metformin—type 2 diabetes mellitus	0.000146	0.000795	CcSEcCtD
Lisdexamfetamine—Angioedema—Ramipril—type 2 diabetes mellitus	0.000146	0.000793	CcSEcCtD
Lisdexamfetamine—Anorexia—Losartan—type 2 diabetes mellitus	0.000145	0.000787	CcSEcCtD
Lisdexamfetamine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000145	0.000787	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000144	0.000782	CcSEcCtD
Lisdexamfetamine—Rash—Glyburide—type 2 diabetes mellitus	0.000143	0.00078	CcSEcCtD
Lisdexamfetamine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000143	0.00078	CcSEcCtD
Lisdexamfetamine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000143	0.00078	CcSEcCtD
Lisdexamfetamine—Headache—Glyburide—type 2 diabetes mellitus	0.000143	0.000775	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000142	0.000772	CcSEcCtD
Lisdexamfetamine—Palpitations—Ramipril—type 2 diabetes mellitus	0.000141	0.000767	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.00014	0.000763	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.00014	0.00076	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000139	0.000757	CcSEcCtD
Lisdexamfetamine—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000139	0.000756	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000138	0.000752	CcSEcCtD
Lisdexamfetamine—Convulsion—Ramipril—type 2 diabetes mellitus	0.000138	0.000752	CcSEcCtD
Lisdexamfetamine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000138	0.00075	CcSEcCtD
Lisdexamfetamine—Insomnia—Losartan—type 2 diabetes mellitus	0.000137	0.000747	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000137	0.000743	CcSEcCtD
Lisdexamfetamine—Urticaria—Metformin—type 2 diabetes mellitus	0.000136	0.000739	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000135	0.000736	CcSEcCtD
Lisdexamfetamine—Anxiety—Ramipril—type 2 diabetes mellitus	0.000135	0.000736	CcSEcCtD
Lisdexamfetamine—Nausea—Glyburide—type 2 diabetes mellitus	0.000135	0.000735	CcSEcCtD
Lisdexamfetamine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000135	0.000735	CcSEcCtD
Lisdexamfetamine—Somnolence—Losartan—type 2 diabetes mellitus	0.000135	0.000734	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000135	0.000733	CcSEcCtD
Lisdexamfetamine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000135	0.000732	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000134	0.000727	CcSEcCtD
Lisdexamfetamine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000133	0.000724	CcSEcCtD
Lisdexamfetamine—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000133	0.000722	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000132	0.000718	CcSEcCtD
Lisdexamfetamine—Fatigue—Losartan—type 2 diabetes mellitus	0.000131	0.000712	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00013	0.000708	CcSEcCtD
Lisdexamfetamine—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00013	0.000707	CcSEcCtD
Lisdexamfetamine—Constipation—Losartan—type 2 diabetes mellitus	0.00013	0.000706	CcSEcCtD
Lisdexamfetamine—Rash—Gliclazide—type 2 diabetes mellitus	0.000129	0.000701	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000129	0.0007	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000128	0.000699	CcSEcCtD
Lisdexamfetamine—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000128	0.000697	CcSEcCtD
Lisdexamfetamine—Headache—Gliclazide—type 2 diabetes mellitus	0.000128	0.000696	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000128	0.000694	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000127	0.000694	CcSEcCtD
Lisdexamfetamine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000127	0.000691	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000127	0.00069	CcSEcCtD
Lisdexamfetamine—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000126	0.000688	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000126	0.000684	CcSEcCtD
Lisdexamfetamine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000124	0.000675	CcSEcCtD
Lisdexamfetamine—Anorexia—Ramipril—type 2 diabetes mellitus	0.000124	0.000675	CcSEcCtD
Lisdexamfetamine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000123	0.000667	CcSEcCtD
Lisdexamfetamine—Asthenia—Metformin—type 2 diabetes mellitus	0.000123	0.000667	CcSEcCtD
Lisdexamfetamine—Nausea—Gliclazide—type 2 diabetes mellitus	0.000121	0.00066	CcSEcCtD
Lisdexamfetamine—Urticaria—Losartan—type 2 diabetes mellitus	0.000121	0.000656	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Losartan—type 2 diabetes mellitus	0.00012	0.000653	CcSEcCtD
Lisdexamfetamine—Vomiting—Valsartan—type 2 diabetes mellitus	0.000119	0.000649	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000119	0.000646	CcSEcCtD
Lisdexamfetamine—Rash—Valsartan—type 2 diabetes mellitus	0.000118	0.000644	CcSEcCtD
Lisdexamfetamine—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000118	0.000643	CcSEcCtD
Lisdexamfetamine—Vomiting—Orlistat—type 2 diabetes mellitus	0.000118	0.000641	CcSEcCtD
Lisdexamfetamine—Insomnia—Ramipril—type 2 diabetes mellitus	0.000118	0.00064	CcSEcCtD
Lisdexamfetamine—Headache—Valsartan—type 2 diabetes mellitus	0.000118	0.00064	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000117	0.000636	CcSEcCtD
Lisdexamfetamine—Rash—Orlistat—type 2 diabetes mellitus	0.000117	0.000636	CcSEcCtD
Lisdexamfetamine—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000117	0.000635	CcSEcCtD
Lisdexamfetamine—Headache—Orlistat—type 2 diabetes mellitus	0.000116	0.000632	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000116	0.000631	CcSEcCtD
Lisdexamfetamine—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000116	0.000629	CcSEcCtD
Lisdexamfetamine—Somnolence—Ramipril—type 2 diabetes mellitus	0.000116	0.000629	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000115	0.000623	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000113	0.000615	CcSEcCtD
Lisdexamfetamine—Dizziness—Metformin—type 2 diabetes mellitus	0.000113	0.000615	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000112	0.000611	CcSEcCtD
Lisdexamfetamine—Fatigue—Ramipril—type 2 diabetes mellitus	0.000112	0.00061	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000112	0.000608	CcSEcCtD
Lisdexamfetamine—Nausea—Valsartan—type 2 diabetes mellitus	0.000111	0.000606	CcSEcCtD
Lisdexamfetamine—Constipation—Ramipril—type 2 diabetes mellitus	0.000111	0.000605	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.00011	0.0006	CcSEcCtD
Lisdexamfetamine—Nausea—Orlistat—type 2 diabetes mellitus	0.00011	0.000599	CcSEcCtD
Lisdexamfetamine—Asthenia—Losartan—type 2 diabetes mellitus	0.000109	0.000592	CcSEcCtD
Lisdexamfetamine—Vomiting—Metformin—type 2 diabetes mellitus	0.000109	0.000591	CcSEcCtD
Lisdexamfetamine—Rash—Metformin—type 2 diabetes mellitus	0.000108	0.000586	CcSEcCtD
Lisdexamfetamine—Dermatitis—Metformin—type 2 diabetes mellitus	0.000108	0.000586	CcSEcCtD
Lisdexamfetamine—Headache—Metformin—type 2 diabetes mellitus	0.000107	0.000582	CcSEcCtD
Lisdexamfetamine—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000107	0.00058	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP3A4—type 2 diabetes mellitus	0.000105	0.0245	CrCbGaD
Lisdexamfetamine—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000104	0.000565	CcSEcCtD
Lisdexamfetamine—Urticaria—Ramipril—type 2 diabetes mellitus	0.000103	0.000562	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000103	0.00056	CcSEcCtD
Lisdexamfetamine—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000103	0.000558	CcSEcCtD
Lisdexamfetamine—Rash—Irbesartan—type 2 diabetes mellitus	0.000102	0.000553	CcSEcCtD
Lisdexamfetamine—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000102	0.000553	CcSEcCtD
Lisdexamfetamine—Nausea—Metformin—type 2 diabetes mellitus	0.000102	0.000552	CcSEcCtD
Lisdexamfetamine—Headache—Irbesartan—type 2 diabetes mellitus	0.000101	0.00055	CcSEcCtD
Lisdexamfetamine—Dizziness—Losartan—type 2 diabetes mellitus	0.0001	0.000546	CcSEcCtD
Lisdexamfetamine—Vomiting—Losartan—type 2 diabetes mellitus	9.65e-05	0.000525	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	9.59e-05	0.000522	CcSEcCtD
Lisdexamfetamine—Nausea—Irbesartan—type 2 diabetes mellitus	9.58e-05	0.000521	CcSEcCtD
Lisdexamfetamine—Rash—Losartan—type 2 diabetes mellitus	9.57e-05	0.000521	CcSEcCtD
Lisdexamfetamine—Dermatitis—Losartan—type 2 diabetes mellitus	9.56e-05	0.00052	CcSEcCtD
Lisdexamfetamine—Headache—Losartan—type 2 diabetes mellitus	9.51e-05	0.000517	CcSEcCtD
Lisdexamfetamine—Asthenia—Ramipril—type 2 diabetes mellitus	9.34e-05	0.000508	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP3A4—type 2 diabetes mellitus	9.27e-05	0.0216	CrCbGaD
Lisdexamfetamine—Nausea—Losartan—type 2 diabetes mellitus	9.02e-05	0.00049	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.9e-05	0.000484	CcSEcCtD
Lisdexamfetamine—Dizziness—Ramipril—type 2 diabetes mellitus	8.61e-05	0.000468	CcSEcCtD
Lisdexamfetamine—Vomiting—Ramipril—type 2 diabetes mellitus	8.27e-05	0.00045	CcSEcCtD
Lisdexamfetamine—Rash—Ramipril—type 2 diabetes mellitus	8.21e-05	0.000446	CcSEcCtD
Lisdexamfetamine—Dermatitis—Ramipril—type 2 diabetes mellitus	8.2e-05	0.000446	CcSEcCtD
Lisdexamfetamine—Headache—Ramipril—type 2 diabetes mellitus	8.15e-05	0.000444	CcSEcCtD
Lisdexamfetamine—Nausea—Ramipril—type 2 diabetes mellitus	7.73e-05	0.000421	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	6.2e-05	0.00101	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	6.18e-05	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—type 2 diabetes mellitus	6.17e-05	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—type 2 diabetes mellitus	6.17e-05	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—type 2 diabetes mellitus	6.11e-05	0.000996	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	6.1e-05	0.000994	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	6.09e-05	0.000993	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—type 2 diabetes mellitus	6.08e-05	0.000992	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	6.06e-05	0.000987	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKCB—type 2 diabetes mellitus	6.04e-05	0.000984	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	6.03e-05	0.000983	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	5.92e-05	0.000965	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	5.9e-05	0.000962	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	5.9e-05	0.000962	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	5.89e-05	0.000959	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	5.87e-05	0.000958	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—type 2 diabetes mellitus	5.87e-05	0.000957	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GNB3—type 2 diabetes mellitus	5.83e-05	0.00095	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CALM1—type 2 diabetes mellitus	5.83e-05	0.00095	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	5.81e-05	0.000947	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	5.64e-05	0.00092	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	5.62e-05	0.000917	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	5.53e-05	0.000901	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—PRKCB—type 2 diabetes mellitus	5.47e-05	0.000892	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—AGT—type 2 diabetes mellitus	5.45e-05	0.000888	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	5.28e-05	0.00086	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	5.28e-05	0.00086	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	5.26e-05	0.000857	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	5.23e-05	0.000853	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—IAPP—type 2 diabetes mellitus	5.23e-05	0.000852	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—ADCY5—type 2 diabetes mellitus	5.2e-05	0.000847	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	5.19e-05	0.000845	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	5.18e-05	0.000844	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	5.18e-05	0.000844	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	5.15e-05	0.00084	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	5.12e-05	0.000835	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GCGR—type 2 diabetes mellitus	5.11e-05	0.000833	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	5.09e-05	0.00083	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	5.08e-05	0.000827	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	5.01e-05	0.000817	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	4.9e-05	0.000798	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—type 2 diabetes mellitus	4.87e-05	0.000794	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	4.86e-05	0.000792	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARAP1—type 2 diabetes mellitus	4.83e-05	0.000788	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	4.73e-05	0.000772	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	4.72e-05	0.000769	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRK5—type 2 diabetes mellitus	4.7e-05	0.000766	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GIPR—type 2 diabetes mellitus	4.7e-05	0.000766	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	4.69e-05	0.000764	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	4.68e-05	0.000762	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	4.68e-05	0.000762	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	4.59e-05	0.000748	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	4.57e-05	0.000745	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	4.56e-05	0.000744	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GIP—type 2 diabetes mellitus	4.56e-05	0.000743	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	4.54e-05	0.00074	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—type 2 diabetes mellitus	4.53e-05	0.000739	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	4.51e-05	0.000735	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	4.49e-05	0.000732	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	4.49e-05	0.000731	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GHRL—type 2 diabetes mellitus	4.47e-05	0.000729	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CALM1—type 2 diabetes mellitus	4.46e-05	0.000728	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VPS26A—type 2 diabetes mellitus	4.42e-05	0.000721	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CALCA—type 2 diabetes mellitus	4.42e-05	0.00072	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	4.35e-05	0.000708	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—type 2 diabetes mellitus	4.33e-05	0.000706	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MC4R—type 2 diabetes mellitus	4.3e-05	0.000701	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	4.28e-05	0.000698	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	4.23e-05	0.000689	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKCB—type 2 diabetes mellitus	4.19e-05	0.000684	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—type 2 diabetes mellitus	4.18e-05	0.000681	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	4.16e-05	0.000678	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GIP—type 2 diabetes mellitus	4.14e-05	0.000675	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	4.1e-05	0.000669	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GCG—type 2 diabetes mellitus	4.09e-05	0.000667	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—type 2 diabetes mellitus	4.08e-05	0.000665	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3R1—type 2 diabetes mellitus	4e-05	0.000652	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	3.98e-05	0.000648	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	3.97e-05	0.000646	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	3.88e-05	0.000633	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	3.88e-05	0.000632	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	3.8e-05	0.000619	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	3.79e-05	0.000618	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	3.74e-05	0.00061	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—type 2 diabetes mellitus	3.7e-05	0.000603	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	3.69e-05	0.000601	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	3.64e-05	0.000593	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	3.61e-05	0.000588	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—type 2 diabetes mellitus	3.58e-05	0.000583	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	3.54e-05	0.000577	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNB3—type 2 diabetes mellitus	3.53e-05	0.000575	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	3.52e-05	0.000574	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	3.52e-05	0.000574	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	3.5e-05	0.00057	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	3.49e-05	0.000569	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AVP—type 2 diabetes mellitus	3.48e-05	0.000567	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	3.42e-05	0.000558	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	3.4e-05	0.000554	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	3.37e-05	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	3.34e-05	0.000544	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDN1—type 2 diabetes mellitus	3.31e-05	0.000539	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	3.28e-05	0.000535	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	3.15e-05	0.000514	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	3.14e-05	0.000512	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	3.13e-05	0.000511	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	3.12e-05	0.000508	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	3.11e-05	0.000507	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	3.09e-05	0.000504	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	3.03e-05	0.000494	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GCGR—type 2 diabetes mellitus	3.02e-05	0.000492	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	2.99e-05	0.000487	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	2.98e-05	0.000486	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	2.97e-05	0.000484	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR5—type 2 diabetes mellitus	2.96e-05	0.000482	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	2.95e-05	0.000482	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—C3—type 2 diabetes mellitus	2.89e-05	0.000471	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	2.89e-05	0.00047	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	2.87e-05	0.000468	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	2.85e-05	0.000464	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	2.79e-05	0.000455	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GIPR—type 2 diabetes mellitus	2.78e-05	0.000453	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRK5—type 2 diabetes mellitus	2.78e-05	0.000453	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	2.75e-05	0.000448	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGT—type 2 diabetes mellitus	2.75e-05	0.000448	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IAPP—type 2 diabetes mellitus	2.68e-05	0.000437	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	2.67e-05	0.000435	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	2.67e-05	0.000435	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	2.62e-05	0.000427	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	2.6e-05	0.000425	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	2.59e-05	0.000423	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MC4R—type 2 diabetes mellitus	2.54e-05	0.000414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	2.54e-05	0.000414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	2.53e-05	0.000412	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	2.52e-05	0.000411	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	2.5e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	2.49e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GIP—type 2 diabetes mellitus	2.44e-05	0.000398	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	2.42e-05	0.000395	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	2.36e-05	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	2.36e-05	0.000384	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEPR—type 2 diabetes mellitus	2.32e-05	0.000379	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—type 2 diabetes mellitus	2.32e-05	0.000378	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GCG—type 2 diabetes mellitus	2.31e-05	0.000377	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	2.31e-05	0.000376	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GHRL—type 2 diabetes mellitus	2.3e-05	0.000374	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	2.27e-05	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CALCA—type 2 diabetes mellitus	2.27e-05	0.00037	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL2—type 2 diabetes mellitus	2.26e-05	0.000369	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	2.22e-05	0.000362	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TLE4—type 2 diabetes mellitus	2.16e-05	0.000352	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	2.11e-05	0.000345	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GCG—type 2 diabetes mellitus	2.1e-05	0.000342	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB3—type 2 diabetes mellitus	2.08e-05	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	2.07e-05	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRHR1—type 2 diabetes mellitus	2.01e-05	0.000327	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	1.99e-05	0.000325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AVP—type 2 diabetes mellitus	1.97e-05	0.00032	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.87e-05	0.000305	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	1.87e-05	0.000305	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	1.85e-05	0.000302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPRY2—type 2 diabetes mellitus	1.84e-05	0.000299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	1.84e-05	0.000299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNB3—type 2 diabetes mellitus	1.81e-05	0.000295	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RBP4—type 2 diabetes mellitus	1.79e-05	0.000292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLP1R—type 2 diabetes mellitus	1.79e-05	0.000292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AVP—type 2 diabetes mellitus	1.79e-05	0.000291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MMP3—type 2 diabetes mellitus	1.79e-05	0.000291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—type 2 diabetes mellitus	1.78e-05	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	1.78e-05	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCKAR—type 2 diabetes mellitus	1.76e-05	0.000287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDN1—type 2 diabetes mellitus	1.7e-05	0.000277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	1.67e-05	0.000272	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—C3—type 2 diabetes mellitus	1.63e-05	0.000266	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	1.61e-05	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	1.59e-05	0.00026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IAPP—type 2 diabetes mellitus	1.59e-05	0.000258	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INSR—type 2 diabetes mellitus	1.58e-05	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGT—type 2 diabetes mellitus	1.55e-05	0.000253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRPC6—type 2 diabetes mellitus	1.55e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	1.55e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.54e-05	0.000251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.52e-05	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—C3—type 2 diabetes mellitus	1.48e-05	0.000242	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.47e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.43e-05	0.000234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.43e-05	0.000233	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.43e-05	0.000233	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.41e-05	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.39e-05	0.000227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.39e-05	0.000226	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.39e-05	0.000226	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.36e-05	0.000222	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.36e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.36e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.34e-05	0.000218	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.3e-05	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.26e-05	0.000206	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.26e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GCG—type 2 diabetes mellitus	1.24e-05	0.000202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.24e-05	0.000202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.22e-05	0.000199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.22e-05	0.000198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.16e-05	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.14e-05	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.14e-05	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.08e-05	0.000176	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.07e-05	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.05e-05	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.05e-05	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.05e-05	0.000171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.05e-05	0.00017	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.03e-05	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.02e-05	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.02e-05	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDN1—type 2 diabetes mellitus	1e-05	0.000164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPL—type 2 diabetes mellitus	9.73e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.53e-06	0.000155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.13e-06	0.000149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.97e-06	0.000146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—C3—type 2 diabetes mellitus	8.76e-06	0.000143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.36e-06	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.34e-06	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGT—type 2 diabetes mellitus	8.33e-06	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.19e-06	0.000133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOE—type 2 diabetes mellitus	8.16e-06	0.000133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—type 2 diabetes mellitus	8.16e-06	0.000133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.06e-06	0.000131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.69e-06	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.28e-06	0.000119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INS—type 2 diabetes mellitus	6.97e-06	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.86e-06	0.000112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.74e-06	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.74e-06	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.71e-06	0.000109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.4e-06	0.000104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.11e-06	9.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.11e-06	9.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	5.75e-06	9.38e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.24e-06	8.54e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.19e-06	8.46e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.16e-06	8.4e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.9e-06	7.99e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.85e-06	7.91e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.76e-06	7.75e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.52e-06	7.37e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.4e-06	7.18e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.04e-06	6.59e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.96e-06	6.46e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.05e-06	4.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.81e-06	4.58e-05	CbGpPWpGaD
